NLS Pharmaceutics AG
NLSPW0.014USD
0.000
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of NLS Pharmaceutics AG Company
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Company Info
Ticker SymbolNLSPW
Company nameNLS Pharmaceutics AG
IPO dateJan 29, 2021
CEOMr. Alexander Zwyer
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressThe Circle 6
CityZUERICH
Stock exchangeNASDAQ Capital Market Consolidated
CountrySwitzerland
Postal code8058
Phone41445122150
Websitehttps://nlspharma.com/
Ticker SymbolNLSPW
IPO dateJan 29, 2021
CEOMr. Alexander Zwyer
Company Executives
Name
Name/Position
Position
Shareholding
Change
,
,
Independent Director
Independent Director
--
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Dr. Eric Konofal, M.D., Ph.D
Dr. Eric Konofal, M.D., Ph.D
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
--
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
Independent Director
Independent Director
--
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Dr. Eric Konofal, M.D., Ph.D
Dr. Eric Konofal, M.D., Ph.D
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Feb 23
Updated: Sun, Feb 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
9
258.62K
0.00%
-535.48K
2025Q1
9
258.62K
0.00%
-535.48K
2024Q4
9
575.86K
0.00%
+75.79K
2024Q3
10
481.82K
0.00%
-1.36M
2024Q2
12
1.16M
0.00%
-830.95K
2024Q1
11
1.15M
0.00%
-822.65K
2023Q4
10
1.13M
0.00%
-839.40K
2023Q3
10
1.13M
0.00%
-844.05K
2023Q2
10
1.13M
0.00%
-844.05K
2023Q1
10
1.13M
0.00%
-835.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wolverine Asset Management, LLC
--
0%
-245.00K
-100.00%
Mar 31, 2025
Hudson Bay Capital Management LP
--
0%
-71.36K
-100.00%
Mar 31, 2025
Clear Street LLC
57.64K
0%
-300.00
-0.52%
Mar 31, 2025
Citadel Advisors LLC
18.38K
0%
-577.00
-3.04%
Mar 31, 2025
Armistice Capital LLC
12.50K
0%
--
--
Mar 31, 2025
Altium Capital Management LP
--
0%
-200.00K
-100.00%
Dec 31, 2024
Susquehanna International Group, LLP
--
0%
-12.22K
-100.00%
Sep 30, 2024
UBS Financial Services, Inc.
--
0%
-6.02K
-100.00%
Jun 30, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
